1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Trauma - Pipeline Review, H1 2015

Trauma - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 45 pages

Trauma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Trauma - Pipeline Review, H1 2015’, provides an overview of the Trauma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Trauma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Trauma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Trauma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Trauma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Trauma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Trauma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Trauma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Trauma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Trauma - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Trauma Overview 6
Therapeutics Development 7
Pipeline Products for Trauma - Overview 7
Pipeline Products for Trauma - Comparative Analysis 8
Trauma - Therapeutics under Development by Companies 9
Trauma - Therapeutics under Investigation by Universities/Institutes 10
Trauma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Trauma - Products under Development by Companies 13
Trauma - Products under Investigation by Universities/Institutes 14
Trauma - Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Bionature E.A. Ltd. 16
Edge Therapeutics, Inc. 17
SanBio, Inc. 18
Trauma - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
EG-1962 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
MEDI-8111 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
PT-00114 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
PT-00311 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
SB-308 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Small Molecules to Agonize Neurotrophin Receptor for CNS and Ophthalmological Disorders - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
TPX-100 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Trauma - Recent Pipeline Updates 39
Trauma - Dormant Projects 41
Trauma - Discontinued Products 42
Trauma - Product Development Milestones 43
Featured News and Press Releases 43
Jun 10, 2013: Edge Therapeutics Announces FDA Accepts IND Application For EG-1962 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables

Number of Products under Development for Trauma, H1 2015 7
Number of Products under Development for Trauma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Trauma - Pipeline by AstraZeneca PLC, H1 2015 15
Trauma - Pipeline by Bionature E.A. Ltd., H1 2015 16
Trauma - Pipeline by Edge Therapeutics, Inc., H1 2015 17
Trauma - Pipeline by SanBio, Inc., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Trauma Therapeutics - Recent Pipeline Updates, H1 2015 39
Trauma - Dormant Projects, H1 2015 41
Trauma - Discontinued Products, H1 2015 42

List of Figures

Number of Products under Development for Trauma, H1 2015 7
Number of Products under Development for Trauma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Top 10 Routes of Administration, H1 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Epilepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.